Escitalopram Oxalate

The 1st China Pharmaceutical Innovation Conference (CPIC), organized by TONACEA, will be grandly held from July 22 to 24, 2026, at the National Exhibition and Convention Center (Shanghai).Benchmarking the J.P. Morgan Healthcare Conference, CPIC aims to establish a new paradigm of “China Innovation – Global Translation – Shanghai as a Global Deal-Making Hub.” Global biotech innovation now features a distinct trans-Pacific synergy: the West leads "zero-to-one" basic scientific breakthroughs, while China delivers fast, high-quality translational and clinical development. This complementary “Trans-Pacific Biotech Relay” model enables capital-efficient, affordable innovative drug development, reshaping the global biotech landscape. Against this backdrop, Tonacea living room presents Episode 10 of the CPIC Live Series: The West-East Biotech Relay — Accelerating Affordable Innovation, streaming live 21:00–22:00, Tuesday, July 14 (Beijing Time). The session will focus on three core pillars of global biotech collaboration: 1.The "Zero-to-One" Engine: Breakthroughs in basic research and bridging the academic research to biotech startups through company formation and early-stage investment. 2.The Acceleration Engine: Leveraging China’s speed and efficiency in early R&D without compromising data quality. 3.The Commercial Muscle: Strategies for late-stage global trials and navigating the capital markets. Tune in to uncover the new paradigm of win-win trans-Pacific biotech innovation and collaboration. Anna French Managing Partner of Qiming Venture Partners US She joined the firm in 2017 and currently serves on the boards of Umoja Biopharma, Empirico Inc., Renasant Bio, Altis Labs, Auron Therapeutics, Entact Bio, and Montage Bio. She led Qiming’s investment in Cadent Therapeutics (acquired by Novartis) and Jasper Therapeutics (NASDAQ:JSPR). Anna joined Qiming US from the Boston Consulting Group (BCG), where she was a healthcare management consultant advising leading biopharma companies on their strategy and operations. Previously, she led a global industry-academic consortium centered on cell therapy commercialization, the Centre for the Advancement of Sustainable Medical Innovation (CASMI)’s Translational Stem Cell Consortium. Anna earned a D.Phil. from the University of Oxford, UK, where her research focused on the hematological differentiation of human-induced pluripotent stem cells. She has authored over 20 publications in the field of stem cell research. Anna received her BSc in Biochemistry with first class honors from the University of Bristol. Andreas Penk Co-founder & CEO of EBT Former President of Pfizer China Dr. Andreas Penk is a trained physician with +30 years of experience in the biopharmaceutical industry across global roles. He has been leading large, complex businesses in Europe, Asia with focus on China and Japan, Australia and Africa/Middle East. In 2021, he retired as the President of Pfizer Biopharmaceuticals Group China.  He co-founded European Biopharma Therapeutics (EBT) in 2022 and has been its CEO since then. EBT specializes in bringing innovative medicines from outside Europe to European cancer patients in need.  Andreas held and holds multiple senior positions in societies and federations as well as Board and advisor roles. With more than 20 years of experience in Oncology and being experienced in managing pharmaceutical core functions from clinical development over manufacturing and commercialization up to access and reimbursement he is a renowned expert in the biopharma field.  Dan Zhang Professor at Fudan University & Chief Scientist of the "PUMC Innovation Harbor" Dr. Dan Zhang is a visionary scientist, entrepreneur, and leading authority in the global biopharmaceutical sector. He currently serves as a Professor at Fudan University and Chief Scientist of the "PUMC Innovation Harbor." Dr. Zhang holds an M.D. from Peking Union Medical College (PUMC) and completed his advanced post-graduate studies at Harvard University and the Wharton School of the University of Pennsylvania。As a prominent entrepreneur who bridges the gap between research, manufacturing, and services, Dr. Zhang successfully founded ClinChoice, a top-tier global Contract Research Organization (CRO), and co-founded Jiangsu Hillgene Biopharma Co., Ltd., a premier cell and gene therapy (CGT) CDMO.Beyond his commercial success, Dr. Zhang has been a pivotal force in aligning China’s pharmaceutical regulatory landscape with global standards. He has deeply participated in national policy consultation, serving as a review expert for China’s "13th Five-Year Plan" National Major Scientific and Technological Special Project for "Significant New Drugs Development," as well as a key expert for the International Council for Harmonisation (ICH).In recognition of his profound impact on driving the innovative development of the biopharmaceutical industry, Dr. Zhang was honored as one of the "2025 Forbes China Industry Growth Leaders." Leon ‘Jun’ Tang Co-Founder of iSWT Community & Founder of ISWT BioAdvisory InScienceWeTrust BioAdvisory(www.iswtb.com), a life sciences consulting company focused on the East-West cross-border BD&L and R&D collaborations in the pharmaceutical industry. ISWT BioAdvisory has advised 30+ biotech companies, investment funds, and other companies in the life sciences industry.  Since Feb 2026, Dr. Tang has been the Vice President of Mianus Accelerator of Mianus Capital (www.mianuscapital.com), a boutique US-based healthcare PE/VC fund currently focused on ophthalmology and also leverages a unique CRO+VC model to make early-stage investment in life sciences to drive innovation through West-East biotech collaboration. Dr. Tang is also the founder of iSWT Community (www.iswtc.org), a US-based nonprofit that has more than 5,000 active members from the Asian biotech community.  Previously, Dr. Tang was the head of BD Search & Evaluation at Shanghai Henlius Biotech, a biotech sell-side analyst at Barclays Investment Bank, and a senior manager at the philanthropic venture fund of Cancer Research Institute of New York.  Dr. Tang has published more than 50 academic papers in prestigious journals like Nature Reviews Drug Discovery, Lancet Oncology, Science Translational Medicine, Nature Communications, Science Advances, PNAS, etc.  Dr. Tang received his bachelor’s degree from Tianjin University and master’s degree from Nankai University in China, a PhD degree from Icahn School of Medicine of Mount Sinai, and postdoctoral training at Memorial Sloan Kettering Cancer Center.  Dr. Tang is well recognized expert in China biotech, and he was featured by Caixin Magazine, China Newsweek, Endpoints News, Fierce Pharma, and many leading investment banks. Leon ‘Jun’ Tang, PhD, is founding partner of InScienceWeTrust BioAdvisory, a consulting firm specializing in cross-border pharmaceutical collaborations.  Since February 2026, he has served as Vice President, Business Development, of Mianus Accelerator business unit of Mianus Capital, focusing on early-stage biotech investment & first-in-human clinical development.  Dr. Tang also founded InScienceWeTrust Community, a U.S.-based nonprofit with over 4,000 members in the life sciences sector.  Previously, he held leadership and analyst roles at Shanghai Henlius Biotech, Barclays Investment Bank, and Cancer Research Institute of New York. He has published 50+ papers in top journals and is recognized as a leading China biotech expert. Registration This livestream is free to attend. Long press and scan the QR code in the image below to quickly register and reserve your spot for the livestream. ( Wechat registration ) ( Zoom registration ) Join the Group Discussion Tonacea Livestream has launched a live discussion group. Please scan the QR code of the livestream assistant below and note [0714] to be invited to join the group. Partnerships Email: media@cpic-shanghai.com Business Cooperation： Jiayuan Li: 17718589627 Zhen Li: 13522802756 Livestream Cooperation： Rui Zhang: 18010079763